Tumor-associated immune response

Tumor-associated immune response describes the collective activity of the immune system in identifying and attempting to eliminate malignant cells within the tumor microenvironment (National Cancer Institute, 2023). This process involves a dynamic interplay between innate immune cells, such as natural killer cells and macrophages, and adaptive immune cells, primarily T and B lymphocytes (Nature Reviews Cancer, 2020). While the immune system can initially control tumor growth through immunosurveillance, tumors often evolve mechanisms of immune evasion, such as the upregulation of inhibitory checkpoint molecules like PD-L1 (Cell, 2015). Modern immunotherapy aims to reinvigorate this response using monoclonal antibodies, cell therapies, and vaccines (Journal of Clinical Oncology, 2021). However, because this term encompasses a wide array of cell types, signaling pathways, and physiological states, it does not represent a single, specific molecular target for drug discovery. Instead, it serves as a conceptual framework for understanding how various therapies modulate the host's defense against cancer (Science, 2018). Therapeutic success in this area is often measured by the restoration of cytotoxic T-cell activity and the reduction of immunosuppressive factors within the tumor (Nature, 2019).

Other names

Anti-tumor immunityCancer immune responseHost anti-tumor responseTumor-infiltrating immune response

Modulation of the immune system's ability to recognize and destroy cancer cells through various pathways such as checkpoint inhibition, agonism of costimulatory receptors, or cytokine signaling (Nature Reviews Drug Discovery, 2022).